Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One-Dose hope for blistering skin disease?

NCT ID NCT00525616

Disease control Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a single cycle of rituximab can control bullous pemphigoid, a severe blistering skin condition. Eighteen adults with steroid-dependent or relapsing disease were enrolled. Researchers checked disease control weekly for a month and then monthly for two years, while also monitoring side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

18 people

The number who actually took part.

Start date

Dec 2008

Finished

Dec 2013

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age \>= 18 and \< 80 * karnofsky \>= 50% * bullous pemphigoid clinical indication * cortico-dependent bullous pemphigoid in relapse for the second time * contraception used in female patient * consent obtained from patient Exclusion Criteria: * localized bullous pemphigoid in relapse (\<400cm2) * pemphigoid of pregnancy * dermatosis with IgA * pemphigoid with mucous damage * pregnant woman or nursing mother * woman able to have a baby and without contraception during the clinical trial period * age \< 18 or \> 80 * karnovsky \< 50% * significant disease or uncontrolled disease * serious antecedents of allergy or anaphylactic reaction with human monoclonal antibody * patient with depletion lymphocytic treatment or with initial rituximab treatment * unstable angina or ischemic heart disease * cardiac insufficiency * cardiac rhythm trouble uncontrolled * evolutive infection * immunodepression * neutrophil polynuclear in blood \< 1.5 G/l and /or platelet blood concentration \< 75G/l * positive HIV serology * positive hepatitis B and / or C serology * concomitant immunodepressor treatment able to induce depletion lymphocytic treatment * no consentment * antecedent of serious chronic or recurrent infection or other underlying pathology able to induce serious infection * antecedent of deep tissue infection occurred the previous year of inclusion

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bullous pemphigoid are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bullous pemphigoid

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bullous pemphigoid

Contacts and locations

Locations

  • Rouen University Hospital, Direction de la Recherche et de l'Innovation,

    Rouen, 76031, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.